ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

MVA-BN-WEV

Also written as “MVA-BN-WEV Dose 1”, “MVA-BN-WEV Dose 2” and “MVA-BN-WEV Dose 3”.

Its studies are mostly in Encephalitis, led by Bavarian Nordic.

Furthest: phase 2, since Mar 6, 20252 company-led studies, 1 open or runningNext primary completion: Feb 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bavarian Nordic21 open or runningphase 2since Mar 6, 2025Oct 16, 2019Feb 2027phase 2 · NCT06899802

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 16, 2019First study: phase 1 study in Encephalomyelitis, EquineFirst studyNCT04131595 · 45 enrolled · United States
  2. Mar 6, 2025Phase 2 study in EncephalitisNCT06899802 · 411 enrolled · United States

Ahead

  1. Feb 2027Primary completion: phase 2 study in EncephalitisNCT06899802

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06899802Encephalitis · United States2Active, not recruitingFeb 2027411
NCT04131595Encephalomyelitis, Equine · United States1CompletedJul 22, 202045

How it is read

Names in the registry

  • “MVA-BN-WEV”, 1 entry
  • “MVA-BN-WEV Dose 1”, 1 entry
  • “MVA-BN-WEV Dose 2”, 1 entry
  • “MVA-BN-WEV Dose 3”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.